Company research
CERUS CORP
CIK 1020214Updated Sep 24, 2026
SecurityCERS · NASDAQ · equity
CERS price & chart
Loading TradingView…
NASDAQ:CERS on TradingView ↗About the company
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U.S., the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the U.S. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 221,859,000Source | 200,917,000Source | 197,748,000Source | 218,092,000Source |
| Property, Plant and Equipment, NetUSD | 9,204,000Source | 7,154,000Source | 8,640,000Source | 10,969,000Source |
| GoodwillUSD | 1,316,000Source | 1,316,000Source | 1,316,000Source | 1,316,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 19,961,000Source | 20,266,000Source | 11,647,000Source | 35,585,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 30,374,000Source | 29,777,000Source | 35,500,000Source | 34,426,000Source |
| Inventory, NetUSD | 56,101,000Source | 38,150,000Source | 39,868,000Source | 29,003,000Source |
| Assets, CurrentUSD | 174,384,000Source | 152,022,000Source | 144,441,000Source | 170,144,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,030,000Source | 3,643,000Source | 3,221,000Source | 4,561,000Source |
| Operating Lease, Right-of-Use AssetUSD | 10,124,000Source | 8,384,000Source | 10,713,000Source | 12,512,000Source |
| Other Assets, NoncurrentUSD | 11,049,000Source | 16,801,000Source | 11,425,000Source | 21,378,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 156,894,000Source | 144,021,000Source | 144,304,000Source | 149,530,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 192,000Source | 186,000Source | 181,000Source | 177,000Source |
| Retained Earnings (Accumulated Deficit)USD | -1,081,155,000Source | -1,065,528,000Source | -1,044,610,000Source | -1,007,121,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -156,000Source | -400,000Source | -1,274,000Source | -2,787,000Source |
| Stockholders' Equity Attributable to ParentUSD | 64,224,000Source | 56,145,000Source | 52,650,000Source | 67,610,000Source |
| Additional Paid in Capital, Common StockUSD | 1,145,343,000Source | 1,121,887,000Source | 1,098,353,000Source | 1,077,341,000Source |
| Liabilities and EquityUSD | 221,859,000Source | 200,917,000Source | 197,748,000Source | 218,092,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 100,801,000Source | 63,608,000Source | 67,521,000Source | 117,058,000Source |
| Operating Lease, Liability, CurrentUSD | 2,905,000Source | 2,275,000Source | 2,452,000Source | 2,105,000Source |
| Accounts Payable, CurrentUSD | 28,008,000Source | 21,695,000Source | 23,842,000Source | 33,002,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,153,000Source | 11,663,000Source | 13,751,000Source | 15,329,000Source |
| Other Liabilities, NoncurrentUSD | 5,395,000Source | 3,888,000Source | 3,236,000Source | 3,499,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 741,000Source | 751,000Source | 794,000Source | 952,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 25,271,000Source | 18,943,000Source | 19,225,000Source | 25,203,000Source |
| Deferred Tax Liabilities, NetUSD | 79,000Source | 1,902,000Source | 2,382,000Source | 2,804,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -15,637,000Source | -20,961,000Source | -37,647,000Source | -42,825,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,426,000Source | 1,855,000Source | 2,599,000Source | 2,984,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 22,867,000Source | 22,867,000Source | 20,271,000Source | 24,456,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 396,000Source | -5,504,000Source | 1,102,000Source | 9,200,000Source |
| Increase (Decrease) in InventoriesUSD | 14,682,000Source | -7,030,000Source | 14,947,000Source | 1,768,000Source |
| Increase (Decrease) in Accounts PayableUSD | 5,725,000Source | -1,477,000Source | -7,335,000Source | -4,905,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 4,837,000Source | 11,359,000Source | -43,168,000Source | -25,615,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -6,165,000Source | -8,130,000Source | 8,624,000Source | 8,464,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 3,729,000Source | 2,837,000Source | 4,597,000Source | 2,000,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 231,000Source | 4,964,000Source | 10,673,000Source | 4,192,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -761,000Source | 8,002,000Source | -23,999,000Source | -13,686,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 20,600,000Source | 21,361,000Source | 13,359,000Source | 37,358,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 8,521,000Source | 9,295,000Source | 9,210,000Source | 5,100,000Source |
| Income Taxes Paid, NetUSD | 301,000Source | — | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 336,000Source | -191,000Source | -128,000Source | -727,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 22,867,000Source | 22,867,000Source | 20,271,000Source | 24,456,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,275,000Source | 370,000Source | -648,000Source | -690,000Source |
| Foreign Currency Transaction Gain (Loss), UnrealizedUSD | -290,000Source | 388,000Source | 685,000Source | -1,911,000Source |
| Gain (Loss) on Disposition of Other AssetsUSD | — | -3,000Source | -65,000Source | — |
| GoodwillUSD | 1,316,000Source | 1,316,000Source | 1,316,000Source | 1,316,000Source |
| Income Tax Expense (Benefit)USD | 354,000Source | 205,000Source | 325,000Source | 488,000Source |
| InterestExpenseNonoperatingUSD | 8,343,000Source | 8,877,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 6,000Source | -7,000Source | -54,000Source | -108,000Source |
| Net Income (Loss) Attributable to ParentUSD | -15,627,000Source | -20,918,000Source | -37,489,000Source | -42,779,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -10,000Source | -43,000Source | -158,000Source | -46,000Source |
| Nonoperating Income (Expense)USD | -6,602,000Source | -6,531,000Source | -7,269,000Source | -8,256,000Source |
| Operating ExpensesUSD | 148,634,000Source | 134,798,000Source | 146,883,000Source | 147,442,000Source |
| Other Nonoperating Income (Expense)USD | 3,016,000Source | 1,976,000Source | 1,765,000Source | -1,735,000Source |
| Payments to Acquire InvestmentsUSD | 42,777,000Source | 42,975,000Source | 2,486,000Source | 29,640,000Source |
| Proceeds from Issuance of Common StockUSD | -35,000Source | -137,000Source | -175,000Source | -104,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | 40,341,000Source | 37,682,000Source | 15,707,000Source | 40,104,000Source |
| Proceeds from Noncontrolling InterestsUSD | — | — | 0Source | — |
| Restructuring CostsUSD | — | 0Source | 3,728,000Source | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 204,000Source | 135,000Source | 170,000Source | 564,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 233,798,000Source | 201,321,000Source | 186,797,000Source | 188,315,000Source |
| Selling, General and Administrative ExpenseUSD | 80,914,000Source | 75,891,000Source | 75,516,000Source | 83,335,000Source |
| Operating Income (Loss)USD | -8,681,000Source | -14,225,000Source | -30,053,000Source | -34,081,000Source |
| Other Nonoperating Income (Expense)USD | 3,016,000Source | 1,976,000Source | 1,765,000Source | -1,735,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -15,283,000Source | -20,756,000Source | -37,322,000Source | -42,337,000Source |
| Income Tax Expense (Benefit)USD | 354,000Source | 205,000Source | 325,000Source | 488,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -10,000Source | -43,000Source | -158,000Source | -46,000Source |
| Net Income (Loss) Attributable to ParentUSD | -15,627,000Source | -20,918,000Source | -37,489,000Source | -42,779,000Source |
| Earnings Per Share, BasicUSD per share | -0.08Source | -0.11Source | -0.21Source | -0.24Source |
| Earnings Per Share, DilutedUSD per share | -0.08Source | -0.11Source | -0.21Source | -0.24Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 190,594,000Source | 184,563,000Source | 180,270,000Source | 176,545,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 190,594,000Source | 184,563,000Source | 180,270,000Source | 176,545,000Source |
| Interest Expense (non-operating)USD | 8,343,000Source | 8,877,000Source | — | — |
| Additional Financial Items | ||||
| Current Income Tax Expense (Benefit)USD | 349,000Source | 200,000Source | 321,000Source | 525,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 2,000,000Source | 2,000,000Source | 2,400,000Source | 2,500,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | -1,275,000Source | 370,000Source | -648,000Source | -690,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -17,709,000Source | -21,318,000Source | -38,281,000Source | -43,096,000Source |
| Interest ExpenseUSD | — | — | 8,386,000Source | 5,831,000Source |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | 6,000Source | -7,000Source | -54,000Source | -108,000Source |
| Nonoperating Income (Expense)USD | -6,602,000Source | -6,531,000Source | -7,269,000Source | -8,256,000Source |
| Operating ExpensesUSD | 148,634,000Source | 134,798,000Source | 146,883,000Source | 147,442,000Source |
| Restructuring CostsUSD | — | 0Source | 3,728,000Source | — |
Filing attachments
cers-ex99_1.htm · 8-K · 2026-07-30
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Second Quarter 2026 Financial Results Second Quarter 2026 Total Revenue of $63.3 million; Second Quarter 2026 Product Revenue of $57.4 million, +10% Y/Y Raising Lower End of 2026 Product Revenue Guidance: Range now $229 to $231 million; Raising 2026 IFC Sales Outlook to $23 to $25 million, up approximately 40% to 50% Y/Y CONCORD, CA, July 30, 2026 - Cerus Corporation (Nasdaq: CERS) announced today financi…
Read attachment ↗cers-ex99_1.htm · 8-K · 2026-04-30
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces First Quarter 2026 Financial Results First Quarter 2026 Total Revenue of $59.9 million, Up 23% Over Prior Year; First Quarter 2026 Product Revenue of $53.7 million, Up 24% Over Prior Year Raising Full Year Product Revenue Guidance Range to $227 million - $231 million, reflecting 10% to 12% year-over-year increase CONCORD, CA, April 30, 2026 - Cerus Corporation (Nasdaq: CERS) announced today financial resu…
Read attachment ↗cers-ex99_1.htm · 8-K · 2026-03-02
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results 2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management CONCORD, CA, March 2, 2026 - Cerus Corporation (Nasdaq: CERS) announced today financial results for its full year and fourth quarter e…
Read attachment ↗cers-ex99_1.htm · 8-K · 2026-01-12
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2025 Product Revenue and Provides Outlook Preliminary Full-Year 2025 Product Revenue of $206.1 Million Full-Year 2026 Product Revenue Expected to be $224 Million to $228 Million, Reflecting 9%-11% Growth, Year-Over-Year CONCORD, CA, January 11, 2026 - Cerus Corporation (Nasdaq: CERS) today announced preliminary product revenue for the fourth quarter and full-year 2…
Read attachment ↗cers-ex99_1.htm · 8-K · 2025-11-06
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million CONCORD, CA, November 6, 2025 - Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quart…
Read attachment ↗cers-ex99_1.htm · 8-K · 2025-08-05
EX-99.1 2 cers-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cerus Corporation Announces Second Quarter 2025 Financial Results Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET CONCORD, CA, August 5, 2025- Cerus Corporation (Nasdaq:CERS) announced financial results for the second quarter ended June 30, 2025, and p…
Read attachment ↗